Abstract

TB is the 9th leading cause of death worldwide above HIV/AIDS. Tuberculosis (TB) management remains challenging due to the emergence of drug-resistant tuberculosis such as MDR-TB and XDR-TB. To improvise therapeutic results for MDR/XDR-TB, 89 nations had started utilizing bedaquiline and 54 had utilized delamanid by June 2017. Unfortunately, cardiac arrhythmia was found to be the most serious side effect associated with the both drugs restricting their use for the management of MDR- and XDR-TB. The current review discussed the clinically trialed and approved drug for the treatment of XDR-TB, recently reported compounds against XDR-TB, their synthesis and activity spectrum. This information could be helpful to the medicinal chemist in synthesizing the best XDR-TB inhibitors free from resistance and toxicity.

中文翻译：

---

广泛耐药结核病（XDR-TB）抑制剂克服耐药结核病的祸害：一个角度

摘要

结核病是全世界超过HIV / AIDS的第9大死亡原因。由于耐多药结核病和耐多药结核病的出现，结核病的管理仍然具有挑战性。为了改善MDR / XDR-TB的治疗效果，到2017年6月，已有89个国家开始使用苯达喹啉，而54个国家使用了地拉曼胺。耐多药和广泛耐药结核。本篇综述讨论了治疗XDR-TB的临床试验和批准的药物，最近报道了抗XDR-TB的化合物，其合成和活性谱。该信息可能对药物化学家合成无耐药性和毒性的最佳XDR-TB抑制剂有帮助。